163 related articles for article (PubMed ID: 26592690)
1. Prostate cancer screening practices and diagnoses in patients age 50 and older, Southeastern Michigan, pre/post 2012.
Rezaee ME; Ward CE; Odom BD; Pollock M
Prev Med; 2016 Jan; 82():73-6. PubMed ID: 26592690
[TBL] [Abstract][Full Text] [Related]
2. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.
Cohn JA; Wang CE; Lakeman JC; Silverstein JC; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
Urol Oncol; 2014 Jan; 32(1):41.e23-30. PubMed ID: 23911680
[TBL] [Abstract][Full Text] [Related]
3. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
5. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
Eapen RS; Herlemann A; Washington SL; Cooperberg MR
Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
[TBL] [Abstract][Full Text] [Related]
6. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
[TBL] [Abstract][Full Text] [Related]
7. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2012 Jul; 157(2):120-34. PubMed ID: 22801674
[TBL] [Abstract][Full Text] [Related]
8. State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update.
Vetterlein MW; Dalela D; Sammon JD; Karabon P; Sood A; Jindal T; Meyer CP; Löppenberg B; Sun M; Trinh QD; Menon M; Abdollah F
Urology; 2018 Feb; 112():56-65. PubMed ID: 29056579
[TBL] [Abstract][Full Text] [Related]
9. Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening.
Hutchinson R; Akhtar A; Haridas J; Bhat D; Roehrborn C; Lotan Y
Cancer; 2016 Dec; 122(24):3785-3793. PubMed ID: 27658175
[TBL] [Abstract][Full Text] [Related]
10. Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.
Banerji JS; Wolff EM; Massman JD; Odem-Davis K; Porter CR; Corman JM
J Urol; 2016 Jan; 195(1):66-73. PubMed ID: 26254722
[TBL] [Abstract][Full Text] [Related]
11. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
Drazer MW; Huo D; Eggener SE
J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.
Squiers LB; Bann CM; Dolina SE; Tzeng J; McCormack L; Kamerow D
Am J Prev Med; 2013 Aug; 45(2):182-9. PubMed ID: 23867025
[TBL] [Abstract][Full Text] [Related]
13. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
[TBL] [Abstract][Full Text] [Related]
14. Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.
Barocas DA; Mallin K; Graves AJ; Penson DF; Palis B; Winchester DP; Chang SS
J Urol; 2015 Dec; 194(6):1587-93. PubMed ID: 26087383
[TBL] [Abstract][Full Text] [Related]
15. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
[TBL] [Abstract][Full Text] [Related]
16. US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.
Gejerman G; Ciccone P; Goldstein M; Lanteri V; Schlecker B; Sanzone J; Esposito M; Rome S; Ciccone M; Margolis E; Simon R; Guo Y; Pentakota SR; Sadeghi-Nejad H
Investig Clin Urol; 2017 Nov; 58(6):423-428. PubMed ID: 29124241
[TBL] [Abstract][Full Text] [Related]
17. Changes observed in prostate biopsy practices in an inner city hospital with a high risk patient population following the 2012 uspstf psa screening recommendations.
Tam AW; Khusid J; Inoyatov I; Becerra AZ; Davila J; Chouhan JD; Weiss JP; Hyacinthe LM; McNeil BK; Winer AG
Int Braz J Urol; 2018; 44(4):697-703. PubMed ID: 29617073
[TBL] [Abstract][Full Text] [Related]
18. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
[TBL] [Abstract][Full Text] [Related]
19. Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.
Li J; Berkowitz Z; Hall IJ
J Am Board Fam Med; 2015; 28(4):491-3. PubMed ID: 26152440
[TBL] [Abstract][Full Text] [Related]
20. Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.
Houston KA; King J; Li J; Jemal A
J Urol; 2018 Mar; 199(3):676-682. PubMed ID: 28965781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
